Archive for May 1st, 2012

PLX receives FDA approval. CHTP Northera update

May 01, 2012 No Comments by

Pfizer Inc.(NYSE:PFE) and Protalix BioTherapeutics, Inc. (NYSE-AMEX:PLX, TASE:PLX) announced today that the FDA has approved ELELYSO (taliglucerase alfa) for the long-term treatment of adults with a confirmed diagnosis of type 1 Gaucher disease. The label is available HERE. Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) today gave an update on its Complete Response Letter (CRL) received in March […]

Daily News Read more

CLDX Phase 2b data due May 23. RIGL pipeline update. RPTP ATM sales agreement + GTXI SVNT news

May 01, 2012 No Comments by

Celldex Therapeutics, Inc. (NASDAQ: CLDX) today announced that interim, topline results of the Phase 2b EMERGE study of CDX-011 in patients with advanced breast cancer will be presented in a webcast on May 23, 2012. The company had planned to present these data at the American Society of Clinical Oncology(ASCO) 2012 Annual Meeting. However, due to a clerical error […]

Daily News Read more